Holen Sie sich die Stockscreener-App
3.02
0.33%
0.01
Handel nachbörslich:
3.01
-0.01
-0.33%
Pyxis Oncology Inc Aktie (PYXS) Neueste Nachrichten
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Pyxis Oncology (PYXS) CEO receives 250,956-share performance-based option grant - Stock Titan
Pyxis Oncology Inc (NASDAQ: PYXS) Share Price, PYXS Stock News, PYXS Share Price & Updates - Kalkine
LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Pyxis Oncology Faces Mounting Dilution Risk as Ongoing Equity Raises and Warrants Pressure Shareholder Value - TipRanks
Pyxis Oncology (NASDAQ:PYXS) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPS - MarketBeat
Pyxis Oncology Releases Q2 2026 Financial Results - news.alphastreet.com
Pyxis Oncology Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Pyxis Oncology Q2 loss widens 38%, misses EPS estimate - scanx.trade
Form 8K Pyxis Oncology Inc For: 13 August By Investing.com - Investing.com Nigeria
PYXS: MICVO demonstrates high efficacy and disease control in R/M HNSCC, with pivotal data due in 2026 - TradingView
Pyxis Oncology, Inc. Q2 2026: Revenue $0 EPS $(0.40) — 10-Q Summary - TradingView
Pyxis Oncology Reports $25.3 Million Second-Quarter Net Loss - Quiver Quantitative
Pyxis Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones - The Manila Times
Pyxis Oncology 2Q Research and Development Expenses $16.1M >PYXS - Moomoo
Pyxis Oncology expects two MICVO cancer-study data updates in 2026 - Stock Titan
currently "more than watching" heheheh - Moomoo
Pyxis Oncology Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView
Pyxis Oncology Inc (PYXS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Pyxis Oncology Inc (PYXS) Stock News Today - TradingKey
Price to earnings forward of Pyxis Oncology, Inc. – NASDAQ:PYXS - TradingView
Price to sales forward of Pyxis Oncology, Inc. – NASDAQ:PYXS - TradingView
Pyxis Oncology (PYXS) Projected to Release Quarterly Earnings on Thursday - MarketBeat
Pyxis Oncology (NASDAQ:PYXS) Raised to Strong-Buy at Wells Fargo & Company - MarketBeat
PYXS Initiates Coverage On Wells Fargo -- Rating Set to Overweig - GuruFocus
Wells Fargo initiates Pyxis Oncology stock with overweight rating By Investing.com - Investing.com South Africa
Wells Fargo Initiates Pyxis Oncology at Overweight With $12 Price Target - marketscreener.com
PYXS|Pyxis Oncology Inc|Price:2.910|Chg%:+0.300 - TradingKey
Pyxis Oncology Inc (PYXS) Balance Sheet - TradingKey
Pyxis Oncology Inc (PYXS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pyxis Oncology Inc (PYXS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pyxis Oncology Inc (PYXS) Institutional Confidence - TradingKey
Pyxis Oncology Inc (PYXS) Income Statement - TradingKey
Pyxis Oncology Inc (PYXS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PYXS|Pyxis Oncology Inc|Price:2.610|Chg%:-0.070 - TradingKey
Pyxis Oncology Inc (PYXS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Pyxis Oncology Inc (PYXS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Pyxis Oncology Inc (PYXS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PYXS stock trades steady as Pyxis Oncology highlights cash runway and clinical progress - Ad-hoc-news.de
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Pyxis Oncology Q1 2026 Earnings: Narrower Loss Per Share Drives Positive Stock MovementEarnings Quality Analysis - dars.gov.et
Craig D Gordon Net Worth (2026) - GuruFocus
BIOTECHNOLOGY VALUE FUND L P's Strategic Acquisition in Pyxis Oncology Inc. - GuruFocus
Pyxis Oncology Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Stock ReactionEPS Growth Report - dars.gov.et
Pyxis Oncology: The Market Might Have Already Ruled On Micvotabart Pelidotin - Seeking Alpha
Pyxis Oncology (PYXS) Declines 7.87% as Stock Tests Key Support Near $2.34Percent Above MA - dars.gov.et
Pyxis Oncology (PYXS) Declines Over 7%, Trading Near Critical Support LevelPassive Flow - dars.gov.et
Pyxis Oncology (NASDAQ: PYXS) sees GordonMD entities report over 10M shares and large warrant stake - Stock Titan
Biotechnology Value Fund group (NASDAQ: PYXS) reports 9.99% capped stake in Pyxis - Stock Titan
RBC Capital Reaffirms Their Buy Rating on Pyxis Oncology (PYXS) - The Globe and Mail
RBC Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Pyxis Oncology Company Profile & Introduction - Moomoo
PYXIS ONCOLOGY INC (PYXS) Stock Price & Overview - ChartMill
Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS) and Glaukos (GKOS) - The Globe and Mail
1.80%
1.77%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):